The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (includ…

Primary Immunoglobulin A Nephropathy (IgAN)

~Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT06994845

Phase 2

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria

This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharm…

Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more

~Estimated

~$10 – $8,750

Walden BiosciencesNCT06466135